MediciNova (MNOV) Competitors

MediciNova logo
$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MNOV vs. CGC, BIOA, AMRN, VNDA, and LFCR

Should you buy MediciNova stock or one of its competitors? MediciNova's main competitors and comparable companies include Canopy Growth (CGC), BioAge Labs (BIOA), Amarin (AMRN), Vanda Pharmaceuticals (VNDA), and Lifecore Biomedical (LFCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MediciNova compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, MediciNova had 7 more articles in the media than Canopy Growth. MarketBeat recorded 9 mentions for MediciNova and 2 mentions for Canopy Growth. MediciNova's average media sentiment score of 1.07 beat Canopy Growth's score of 0.78 indicating that MediciNova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Canopy Growth
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MediciNova
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MediciNova has lower revenue, but higher earnings than Canopy Growth. MediciNova is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$308.32M0.69-$190.29M-$0.51N/A
MediciNova$410K166.19-$12M-$0.21N/A

Canopy Growth has a net margin of -73.03% compared to MediciNova's net margin of -1,126.60%. MediciNova's return on equity of -26.47% beat Canopy Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Canopy Growth-73.03% -28.21% -17.97%
MediciNova -1,126.60%-26.47%-24.24%

MediciNova has a consensus price target of $7.75, indicating a potential upside of 482.71%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
MediciNova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Canopy Growth has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 0.4% of Canopy Growth shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

MediciNova beats Canopy Growth on 12 of the 16 factors compared between the two stocks.

How does MediciNova compare to BioAge Labs?

MediciNova (NASDAQ:MNOV) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 482.71%. BioAge Labs has a consensus target price of $29.00, indicating a potential upside of 507.97%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than MediciNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediciNova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

MediciNova has a net margin of -1,126.60% compared to BioAge Labs' net margin of -1,253.60%. MediciNova's return on equity of -26.47% beat BioAge Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
MediciNova-1,126.60% -26.47% -24.24%
BioAge Labs -1,253.60%-31.42%-29.59%

9.9% of MediciNova shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 17.6% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MediciNova has higher earnings, but lower revenue than BioAge Labs. MediciNova is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNova$410K166.19-$12M-$0.21N/A
BioAge Labs$8.99M24.39-$80.61M-$2.55N/A

In the previous week, MediciNova had 5 more articles in the media than BioAge Labs. MarketBeat recorded 9 mentions for MediciNova and 4 mentions for BioAge Labs. MediciNova's average media sentiment score of 1.07 beat BioAge Labs' score of -0.19 indicating that MediciNova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediciNova
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MediciNova has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

MediciNova beats BioAge Labs on 11 of the 16 factors compared between the two stocks.

How does MediciNova compare to Amarin?

MediciNova (NASDAQ:MNOV) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, MediciNova had 5 more articles in the media than Amarin. MarketBeat recorded 9 mentions for MediciNova and 4 mentions for Amarin. MediciNova's average media sentiment score of 1.07 beat Amarin's score of 0.39 indicating that MediciNova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediciNova
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amarin
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MediciNova has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNova$410K166.19-$12M-$0.21N/A
Amarin$176.11M1.35-$38.80M-$0.96N/A

MediciNova currently has a consensus price target of $7.75, suggesting a potential upside of 482.71%. Amarin has a consensus price target of $13.00, suggesting a potential upside of 15.45%. Given MediciNova's stronger consensus rating and higher probable upside, equities research analysts plainly believe MediciNova is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediciNova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Amarin
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33

MediciNova has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Amarin has a net margin of -10.87% compared to MediciNova's net margin of -1,126.60%. Amarin's return on equity of -0.52% beat MediciNova's return on equity.

Company Net Margins Return on Equity Return on Assets
MediciNova-1,126.60% -26.47% -24.24%
Amarin -10.87%-0.52%-0.36%

9.9% of MediciNova shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

MediciNova beats Amarin on 10 of the 16 factors compared between the two stocks.

How does MediciNova compare to Vanda Pharmaceuticals?

MediciNova (NASDAQ:MNOV) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Vanda Pharmaceuticals has a net margin of -119.87% compared to MediciNova's net margin of -1,126.60%. MediciNova's return on equity of -26.47% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MediciNova-1,126.60% -26.47% -24.24%
Vanda Pharmaceuticals -119.87%-62.70%-37.53%

In the previous week, MediciNova had 8 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 9 mentions for MediciNova and 1 mentions for Vanda Pharmaceuticals. MediciNova's average media sentiment score of 1.07 beat Vanda Pharmaceuticals' score of 0.38 indicating that MediciNova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediciNova
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 482.71%. Vanda Pharmaceuticals has a consensus target price of $13.50, indicating a potential upside of 260.00%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than Vanda Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediciNova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

MediciNova has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

9.9% of MediciNova shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MediciNova has higher earnings, but lower revenue than Vanda Pharmaceuticals. MediciNova is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNova$410K166.19-$12M-$0.21N/A
Vanda Pharmaceuticals$216.10M1.05-$220.47M-$4.62N/A

Summary

MediciNova beats Vanda Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does MediciNova compare to Lifecore Biomedical?

MediciNova (NASDAQ:MNOV) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

MediciNova has higher earnings, but lower revenue than Lifecore Biomedical. MediciNova is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNova$410K166.19-$12M-$0.21N/A
Lifecore Biomedical$128.87M1.88-$70.51M-$1.86N/A

MediciNova has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lifecore Biomedical has a net margin of -56.80% compared to MediciNova's net margin of -1,126.60%. Lifecore Biomedical's return on equity of 0.00% beat MediciNova's return on equity.

Company Net Margins Return on Equity Return on Assets
MediciNova-1,126.60% -26.47% -24.24%
Lifecore Biomedical -56.80%N/A -29.53%

In the previous week, MediciNova had 8 more articles in the media than Lifecore Biomedical. MarketBeat recorded 9 mentions for MediciNova and 1 mentions for Lifecore Biomedical. MediciNova's average media sentiment score of 1.07 beat Lifecore Biomedical's score of 0.00 indicating that MediciNova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediciNova
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lifecore Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 482.71%. Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 1.56%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Lifecore Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediciNova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Lifecore Biomedical
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

Summary

MediciNova beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNOV vs. The Competition

MetricMediciNovaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$65.58M$13.16B$7.49B$11.54B
Dividend YieldN/A2.59%2.47%4.65%
P/E Ratio-6.1027.6032.9029.69
Price / Sales70.037.547.935.25
Price / CashN/A15.5920.8521.62
Price / Book1.605.314.403.67
Net Income-$12M$2.88B$3.51B$394.15M
7 Day Performance-8.64%-5.48%-5.70%-5.80%
1 Month Performance-8.64%-6.42%-6.54%-8.19%
1 Year Performance-10.56%-7.56%-2.02%-7.86%

MediciNova Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNOV
MediciNova
2.9133 of 5 stars
$1.28
-3.8%
$7.75
+505.9%
-7.6%$65.58M$935.72KN/A6
CGC
Canopy Growth
1.1404 of 5 stars
$0.59
-4.9%
N/A-53.1%$279.82M$251.01MN/A1,128
BIOA
BioAge Labs
2.5914 of 5 stars
$5.78
+1.6%
$33.00
+470.9%
-42.2%$261.15M$8.60MN/A62
AMRN
Amarin
1.6087 of 5 stars
$11.75
+0.1%
$13.00
+10.6%
-32.6%$247.98M$213.65MN/A80
VNDA
Vanda Pharmaceuticals
3.9613 of 5 stars
$4.08
-0.2%
$13.50
+230.9%
-29.9%$247.32M$216.10MN/A533

Related Companies and Tools


This page (NASDAQ:MNOV) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners